UroGen Pharma (NASDAQ:URGN) Upgraded at HC Wainwright
HC Wainwright upgraded shares of UroGen Pharma (NASDAQ:URGN – Free Report) from a neutral rating to a buy rating in a research note issued to investors on Monday morning, Marketbeat Ratings reports. The brokerage currently has $50.00 price objective on the stock. Several other research firms have also recently issued reports on URGN. Scotiabank lifted […]
HC Wainwright upgraded shares of UroGen Pharma (NASDAQ:URGN – Free Report) from a neutral rating to a buy rating in a research note issued to investors on Monday morning, Marketbeat Ratings reports. The brokerage currently has $50.00 price objective on the stock. Several other research firms have also recently issued reports on URGN. Scotiabank lifted […]
